Nutriband Inc. Receives Intention to Grant' Notice from European Patent Office for Abuse Deterrent Transdermal Technology utilized in the Defent Abuse Deterrent Fentanyl Transdermal System .

Inc. Receives Intention to Grant' Notice from European Patent Office for Abuse Deterrent Transdermal Technology utilized

in the Defent Abuse Deterrent Fentanyl Transdermal System.

Fla., October 31, 2018 - Nutriband Inc. (OTCQB: NTRB), a Nevada corporation, announced today that the European Patent Office

("EPO") has issued a "Notice of Intention to Grant" for European Patent Application EP15740893.1 entitled,

"Abuse and Misuse Deterrent Transdermal System" submitted by its subsidiary, 4P Therapeutics. The patent relates to

the company's proprietary abuse deterrent transdermal technology, utilized in the

Defent fentanyl transdermal system which is being developed at 4P Therapeutics to combat the opioid epidemic.

notification of "Intent to Grant" by the European Patent Office is another step forward in the worldwide prosecution

of our abuse deterrent transdermal technology intellectual property portfolio," said Alan Smith, Ph.D., head of 4P Therapeutics.

Although, opioid abuse in Europe is not as widespread as it is in the United States, studies have shown that the rates of opioid

abuse in Europe may be catching up1. In addition, there are 1.3 million high-risk opioid users in the European Union,

according to a report from the European Monitoring Centre for Drugs and Drug Addiction2.

abuse deterrent patch technology used in the Defent fentanyl transdermal system, is an abuse deterrent platform that the Company

believes can be applied to other type of pain patches and other transdermal products as well to lower the risk of abuse and accidental

misuse through the use of aversive agents, creating a safer treatment option for patients.

is currently developing a portfolio of transdermal pharmaceutical and consumer products through its subsidiary, 4P Therapeutics.

The Company believes that the transdermal route of administration has several advantages over pills and injections including avoidance

of the gastrointestinal tract and related side effects, convenience due to less frequent dosing, and the elimination of the need

for painful injections. 4P's lead product is the Defent abuse deterrent fentanyl transdermal system which is being developed

to combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. In addition, the Company is developing a pipeline

of novel transdermal products for injected peptides and biologics which the Company believes have the potential to improve the

compliance and safety of injectable medications.

Company's website is www.nutriband.com and 4P's website is www.4PTherapeutics.com.

Any material contained in or derived from the Company's or 4P's websites or any other website is not part of this

Our Forward-Looking Statements

statements contained in this press release, including, without limitation, statements containing the words "believes",

"anticipates", "expects" and words of similar import, constitute "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known

and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking

statements as a result of a number of factors, including the Company's ability to develop Defent, the Company's ability

to obtain patent protection in the United States for its abuse technology, its ability to obtain the necessary financing to develop

products and conduct the necessary clinical testing, its ability obtain Federal Food and Drug Administration approval to market

any product it may develop, its ability to market any product it may develop, its ability to create, sustain, manage or forecast

its growth; its ability to attract and retain key personnel; changes in our business strategy or development plans; competition;

business disruptions; adverse publicity and international, national and local general economic and market conditions and risks

generally associated with an undercapitalized development stage company that does not have a product that can be marketed. Except

as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to

reflect any event or circumstance that may arise after the date hereof.

more information, contact: